Discontinued — last reported Q3 '25
Illumina Equity Method Investments increased by 3.4% to $60.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 30.4%, from $46.00M to $60.00M. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows a downward trend with a -28.7% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $338.00M | $61.00M | $40.00M | $41.00M | $42.00M | $42.00M | $28.00M | $28.00M | $28.00M | $28.00M | $28.00M | $28.00M | $28.00M | $27.00M | $26.00M | $46.00M | $46.00M | $58.00M | $58.00M | $60.00M |
| QoQ Change | — | -82.0% | -34.4% | +2.5% | +2.4% | +0.0% | -33.3% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -3.6% | -3.7% | +76.9% | +0.0% | +26.1% | +0.0% | +3.4% |
| YoY Change | — | — | — | — | -87.6% | -31.1% | -30.0% | -31.7% | -33.3% | -33.3% | +0.0% | +0.0% | +0.0% | -3.6% | -7.1% | +64.3% | +64.3% | +114.8% | +123.1% | +30.4% |